Entry

D11108                      Drug

Name

Cemiplimab (USAN);
Cemiplimab (genetical recombination) (JAN);
Cemiplimab-rwlc;
Libtayo (TN)

Product

LIBTAYO (Regeneron Pharmaceuticals)

Sequence

(Heavy chain)
EVQLLESGGV LVQPGGSLRL SCAASGFTFS NFGMTWVRQA PGKGLEWVSG ISGGGRDTYF
ADSVKGRFTI SRDNSKNTLY LQMNSLKGED TAVYYCVKWG NIYFDYWGQG TLVTVSSAST
KGPSVFPLAP CSRSTSESTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
SLSSVVTVPS SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP SQEEMTKNQV
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF
SCSVMHEALH NHYTQKSLSL SLGK
(Light chain)
DIQMTQSPSS LSASVGDSIT ITCRASLSIN TFLNWYQQKP GKAPNLLIYA ASSLHGGVPS
RFSGSGSGTD FTLTIRTLQP EDFATYYCQQ SSNTPFTFGP GTVVDFRRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H131-L214, H144-H200, H223-H'223, H226-H'226, H258-H318, H364-H422, H'22-H'96, H'131-L'214, H'114-H'200, H'258-H'318, H'364-H'422, L23-L88, L134-L194, L'23-L'88, L'134-L'194)

Type

Peptide

Class

Antineoplastic
DG02938 Immune checkpoint inhibitor

Remark

ATC code:

L01FF06

Product:

D11108<US>

Efficacy

Antineoplastic, Anti-PD-1 antibody

Disease

Squamous cell carcinoma [DS:H00040]
Basal cell carcinoma [DS:H00039]
Non-small cell lung cance [DS:H00014]

Comment

Monoclonal antibody
Treatment of cancer

Target

PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]

Pathway

hsa04514

Cell adhesion molecules

hsa04660

T cell receptor signaling pathway

hsa05235

PD-L1 expression and PD-1 checkpoint pathway in cancer

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
     L01FF06 Cemiplimab
      D11108  Cemiplimab (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Cemiplimab
    D11108  Cemiplimab (USAN)
Drug groups [BR:br08330]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D11108  Cemiplimab
Drug classes [BR:br08332]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D11108  Cemiplimab
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D11108  Cemiplimab (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11108
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D11108
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11108
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D11108

Other DBs

CAS:	1801342-60-8

PubChem:

376219032